Bevacizumab vedotin
Based on 1 Customer Validation
Bevacizumab vedotin is an antibody-drug conjugate (ADC). Bevacizumab vedotin blocks the VEGF/VEGFR pathway to exert anti-angiogenic effects. Bevacizumab vedotin exhibits anti-proliferative effects on cancer cells, promotes cancer cell apoptosis (Apoptosis), induces cancer cell cycle arrest, and possesses anti-migratory activity against breast cancer cells. Bevacizumab vedotin can be used in research related to glioma, hepatocellular carcinoma, and breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.72%
- Molecular Weight:149114 (average)
-
Speicherung:
-80°C, protect from light
Alle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
Bevacizumab vedotin (1 mg; 72-120 h) exhibits high serum stability[1].
Bevacizumab vedotin (30-165 min) rapidly and completely releases its MMAE payload under the mediation of cathepsin B[1].
Bevacizumab vedotin (0-10 μg/mL; 48 h) potently inhibits the proliferation of U87, HepG2 and MCF-7 cells, with IC50 values of 14.1712 μg/mL, 0.6483 μg/mL and 0.1442 μg/mL, respectively[1].
Bevacizumab vedotin (1 μg/mL; 48 h) induces apoptosis in U87, HepG2 and MCF-7 cells after 48 h of treatment[1].
Treatment with Bevacizumab vedotin (0.1-20 μg/mL; 48 h) induces G1-phase cell cycle arrest in U87 and HepG2 cells[1].
Bevacizumab vedotin (0.01-0.1 μg/mL; 12-48 h) inhibits the migration of MCF-7 cells in a concentration- and time-dependent manner, and downregulates the expression of VEGF-A in MCF-7 cells[1].
Bevacizumab vedotin (0.1-1 μg/mL; 4-48 h) exhibits anti-angiogenic activity, reduces tube formation (junctions and branches) in HUVECs, downregulates VEGF-A expression, and upregulates VEGFR-2 expression in HUVECs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U87 , HepG2 , MCF-7 cells
-
Concentration:0, 0.01, 0.05, 0.1, 0.2, 0.5, 1, 5, 10 μg/mL
-
Incubation Time:48 h
-
Result:Inhibited proliferation of all three cell lines.
Reached an IC50 of 14.1712 μg/mL for U87 cells.
Reached an IC50 of 0.6483 μg/mL for HepG2 cells.
Reached an IC50 of 0.1442 μg/mL for MCF-7 cells.
-
Cell Line:U87 , HepG2 , MCF-7 cells
-
Concentration:1 μg/mL
-
Incubation Time:48 h
-
Result:Promoted apoptosis in all three cell lines.
Achieved a pro-apoptotic rate of 113% relative to the control group for U87 cells.
Achieved a pro-apoptotic rate of 304% relative to the control group for HepG2 cells.
Achieved a pro-apoptotic rate of 288% relative to the control group for MCF-7 cells.
-
Cell Line:U87 , HepG2 cells
-
Concentration:0.1-20 μg/mL
-
Incubation Time:48 h
-
Result:Induced G1 phase cell cycle arrest in U87 and HepG2 cells.
-
Cell Line:MCF-7 cells
-
Concentration:0, 0.01, 0.02, 0.05, 0.1 μg/mL
-
Incubation Time:0 h, 12 h, 24 h, 36 h and 48 h
-
Result:Enhanced concentration-dependent inhibition of MCF-7 cell migration with increasing incubation time.
-
Cell Line:MCF-7 cells
-
Concentration:0.01, 0.05, 0.1 μg/mL
-
Incubation Time:48 h
-
Result:Caused concentration-dependent downregulation of VEGF-A expression in MCF-7 cells.
-
Cell Line:HUVEC cells
-
Concentration:0.1, 0.5, 1 μg/mL
-
Incubation Time:48 h
-
Result:Caused concentration-dependent downregulation of VEGF-A expression in HUVEC cells.
Caused concentration-dependent upregulation of VEGFR-2 expression in HUVEC cells.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 149114 (average)
-
Color Colorless to light yellow
-
SMILES
[Bevacizumab vedotin]
-
Versand
Shipping with dry ice.
-
Speicherung
-80°C, protect from light
Protokoll
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
-
Data Sheet (272 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)